JMJie Min

Jie Min

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Min has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Albert Roessner

    Department of Pathology Otto-von-Guericke University Magdeberg Germany

    1 shared publication
  • An-Gang Yang

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Immunology, Fourth Military Medical University, Xi’an, China

    1 shared publication
  • Chang-Yu Pu

    1 shared publication
  • Charlie Degui Chen

    State Key Laboratory of Molecular Biology, Shanghai Key Laboratory of Molecular Andrology, Institute of Biochemistry and Cell Biology Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Shanghai China

    1 shared publication
  • Dawei Zhang

    Department of Orthopedics Xijing Hospital, The Fourth Military Medical University Xi'an China

    1 shared publication
  • Degan Lu

    Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, Shandong Institute of Anesthesia and Respiratory Critical Medicine

    1 shared publication

Latest Publications

  • Open Access

    Molecular Characteristics and Treatment Implications of TP53 Gain‐of‐Function Mutations in Non‐Small Cell Lung Cancer

    by Zheng Zhao, Rui Lu, Feng Zhang, Hanlin Chen, Qiuxiang Ou, Xiaotian Zhao, Xinyue Hong, Hua Bao, Degan Lu, Jie Min

    Background: TP53 gain‐of‐function (GOF) effects lead to cellular responses beyond the capabilities of wild‐type TP53 and are known to promote cancer progression, resulting in poorer outcomes in cancer. Methods: A total of 486 patients diagnosed with non‐small cell lung cancer (NSCLC) with baseline DNA sequencing data were enrolled in our study cohort. In addition, clinical and sequencing data from external NSCLC cohorts, including a cohort with histologic data ( N = 219), a combined cohort from two studies treated with immunotherapy ( N = 315), and a cohort treated with ROS1 tyrosine kinase inhibitor (TKI) ( N = 50), were analyzed to assess the relationships between TP53 GOF mutations and histologic subtypes, immunotherapy outcomes, and ROS1‐TKI treatment efficacy. Results: Compared to TP53 non‐GOF mutations, patients with TP53 GOF mutations showed higher mutation rates in PIK3CA , STK11 , and CTNNB1 but lower in NTRK1 ; increased VEGFA but decreased DLL3 and HRAS amplification rates. Patients with TP53 GOF mutations exhibited significantly higher tumor mutation burdens compared to those with non‐GOF TP53 statuses. Patients with TP53 mutations, both GOF and non‐GOF, showed significantly higher expression of immune checkpoints compared to TP53 wild‐type patients. GOF‐mutated patients also had higher M1 macrophage and CD8+ T cell infiltration, along with elevated B cell receptor signaling. Consistent with our findings, analysis of external cohorts revealed that TP53 GOF mutations were associated with improved prognosis in the context of immunotherapy. Among ROS1 fusion‐positive patients treated with ROS1‐TKIs, those harboring TP53 GOF mutations had a longer median PFS compared to patients with non‐GOF TP53, although both were shorter than those with wild‐type TP53. Additionally, TP53 GOF mutations were associated with a relatively lower histologic grade than non‐GOF mutations. Conclusions: TP53 GOF mutations were associated with poorer ROS1‐TKI treatment outcomes but improved immunotherapy response in NSCLC, with elevated immune activities and distinct molecular profiles.


  • Open Access

    Disruption of Jmjd3/p16Ink4a Signaling Pathway Causes Bizarre Parosteal Osteochondromatous Proliferation (BPOP)-like Lesion in Mice

    by Feng Zhang, Yingmei Wang, Yuying Wang, Xinli Wang, Dawei Zhang, Xiong Zhao, Runmin Jiang, Yu Gu, Guifang Yang, Xin Fu, et al.

    Bizarre parosteal osteochondromatous proliferation (BPOP), or Nora's lesion, is a rare benign osteochondromatous lesion. To the present, the molecular aetiology of BPOP remains unclear. JMJD3(KDM6B) is an H3K27me3 demethylase and counteracts polycomb-mediated transcription repression. Previously, Jmjd3 was showed to be critical for bone development and osteoarthritis. Here, we reported that conditional deletion of Jmjd3 in chondrogenic cells unexpectively resulted in BPOP-like lesion in mice. Biochemical investigations revealed that Jmjd3 inhibited BPOP-like lesion through p16Ink4a. Immunohistochemistry and RT-qPCR assays indicated JMJD3 and p16INK4A level were significantly reduced in human BPOP lesion compared to normal subjects. This was further confirmed by Jmjd3/Ink4a double genes knockout mice experiments. Therefore, our results indicated the pathway of Jmjd3/p16Ink4a may be essential for the development of BPOP in human.


    • 1 June 2011
      • Vol. 27  (6) , 611-4

    [The different structure forms of HBx protein influence their intracellular distribution in hepatocellular carcinoma HepG2 cells].

    by Liang Peng, Rui Zhang, Jing Zhao, Jie Min, Chang-Yu Pu, Hou-Long Zhou, An-Gang Yang, Ying-Ming Feng

    Different eukaryotic expression vectors were selected in this research, and then we respectively cloned and constructed recombinant plasmids contained HBX gene or its different fusion forms with GFP. We are aimed to explore the influence of the HBX protein with different structure on its intracellular localization. Flag-HBX gene was amplified from pcDNA3.0-HBX plasmid in our laboratory, cloned into pMD-18T vectors, sequenced.and then subcloned into different vectors. After right sequenced, respective recombinant plasmids of pFlag- HBX-IRES2-EGFP, pEGFP-C3-Flag-HBX and pFlag-HBX-EGFP-N3 were transiently transfected into hepatoma HepG-2 cells. The intra-cellular localizations and distributions of HBX protein were examined by indirect immunofluorescence. Three different Flag-HBX eukaryotic expression vectors were successfully constructed. After transfection of them into HepG2 cells respectively, indirect immunofluorescence demonstrated that HBX protein fused with GFP in different forms show distint intra-cellular distribution characteristics. We have provided significant experimental evidences for research of the role of HBX protein in the development of hepatocellular carcinoma, and especially the references for explanation of the outcomes in vitro transfection experiments.

  • Biological characteristics of a specific brain metastatic cell line derived from human lung adenocarcinoma

    by Ling Hu, Junqing Zhang, Hongbin Zhu, Jie Min, Yingming Feng, Helong Zhang

    To study the expression of VEGF, MMP-9, EGFR, and S100B in a highly brain metastases sub-clone cell line, PC14/B. The in vitro metastases-related behaviors of PC14 /B cells, such as adhesion to extracellular matrix (ECM), migration, and invasion were determined and compared with primary PC14 cells and A549 cells that do not metastasize to brain. The expression of vascular epithelial growth factor (VEGF), matrix metalloproteinase 9 (MMP-9), S100B, and epidermal growth factor receptor (EGFR) in the above three cell lines were measured by immunohistochemical staining and Western blot assay.The PC14/B cells have enhanced abilities of adhesion, migration, and invasion than PC14 cells and A549 cells. The expression levels of VEGF and MMP-9 in PC14/B cells are much higher than in PC14 and A549 cells. Two protein polymers of S100B are expressed specially in PC14/B cells. The expression of EGFR has a significant lower level in PC14 cells than in the other two cell lines. The increased expression of VEGF and MMP-9 may lead to the enhancement of adhesion, migration, and invasion of PC14/B cells. The expression of EGFR in PC14/B cells may have negative correlation with their capacities of metastasizing to brain. The specific expression of S100B in PC14/B cells strongly suggest that S100B might be a potential target for developing new therapy to brain metastases of lung cancer.